Status:
UNKNOWN
URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
Radiation Therapy Oncology Group
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy. Hypothesis: that urinary VEGF levels can serve as a predictor of treat...
Detailed Description
Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment
Eligibility Criteria
Inclusion
- Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
- Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
- Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.
Exclusion
- Patient not able to receive 6000 cGy of radiation therapy.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
End Date :
October 1 2006
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00392548
Start Date
October 1 2006
End Date
October 1 2006
Last Update
October 26 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239